Genflow Biosciences demonstrated that SIRT6 gene therapy reduced biological age in aged dogs as measured by methylation clocking, with improvements sustained across functional measures at three-month follow-up. This represents early evidence that targeted genetic intervention can slow or reverse aging-related decline in mammals, with potential implications for muscle preservation and longevity in aging.
Key Points
- SIRT6 gene therapy reduced biological age in aged beagles versus controls
- Improvements persisted across multiple functional and observable secondary measures
- Safety and efficacy sustained at three-month follow-up in treated animals
Longevity Analysis
The trial addresses a core constraint in aging: the decline of cellular regeneration and energy production that accompanies advancing age. By targeting SIRT6, a gene implicated in metabolic resilience and stress response, the intervention operates at the level of how cells maintain function under the metabolic pressures of aging. The use of methylation clocking as a primary endpoint provides an objective measure of biological age independent of subjective health markers, anchoring the claim to molecular-level change rather than behavioral improvement alone. If these findings translate to larger mammals and humans, they would represent movement beyond symptomatic management toward upstream intervention in the aging process itself—one of the few approaches that could alter the trajectory of age-related decline across multiple tissues simultaneously.
Original published by LT Wire.